MannKind rises as FDA advances rare lung disease therapy to Phase 3 trial [Seeking Alpha]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Seeking Alpha
The U.S. Food and Drug Administration (FDA) cleared MannKind's ( MNKD ) investigational new drug application for MNKD-101, enabling the initiation of a Phase 3 study. This single registrational study, identified as ICoN-1, is likely to commence in the U.S. by the end of the second quarter of 2024, and internationally in the second half of 2024. This placebo-controlled trial will evaluate the efficacy and safety of clofazimine inhalation suspension when added to guideline-based therapy in adults with refractory NTM lung disease caused by mycobacterium avium complex, followed by an open-label extension. Recommended For You More Trending News Recommended For You More Trending News About MNKD Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind Outperforms As Tyvaso DPI Captures Market Share [Seeking Alpha]Seeking Alpha
- MannKind (MNKD) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- MannKind Co. (NASDAQ: MNKD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $6.50 price target on the stock.MarketBeat
- Shareholders May Not Be So Generous With MannKind Corporation's (NASDAQ:MNKD) CEO Compensation And Here's Why [Yahoo! Finance]Yahoo! Finance
MNKD
Earnings
- 5/8/24 - Beat
MNKD
Sec Filings
- 5/14/24 - Form 4
- 5/14/24 - Form 4
- 5/14/24 - Form 4
- MNKD's page on the SEC website